Ceresoli-Borroni G, Kiss C, Guidetti P, Zielke CL, Zielke HR, Schwarcz R (2001)
Kynurenic acid production in cultured human astrocytes. Soc Neurosci Abstr 27:
391.5
Cozzi A, Carpenedo R, Moroni F (1999) Kynurenine hydroxylase inhibitors reduce
ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4- dimethoxy-[-N-4-(nitrophenyl)thiazol-2YL-benzenesulfonamide (Ro 61–8048) in
models of focal or global brain ischemia. J Cereb Blood Flow Metab 19: 771–777
Curatolo L, Caccia C, Speciale C, Raimondi L, Cini M, Marconi M, Molinari A, Schwarcz
R. (1996) Modulation of extracellular kynurenic acid content by excitatory amino
acids in primary cultures of rat astrocytes. In: Allegri Filippini G, Costa CVL,
Bertazzo A (eds) Recent advances in tryptophan research. Plenum Press, New York,
pp 273–276
Denizot FLR (1986) Rapid colorimetric assay for cell growth and survival. Modification
to the tetrazolium dye procedure giving improved sensitivity and reliability. J
Immunol Methods 89: 271–277
Du F, Schmidt W, Okuno E, Kido R, Köhler C, Schwarcz R (1992) Localization of
kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp
Neurol 321: 477–487
Erhardt S, Hajos M, Lindberg A, Engberg G (2000) Nicotine-induced excitation of locus
coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid.
Synapse 37: 104–108
Erhardt S, Öberg H, Engberg G (2001a) Pharmacologically elevated levels of endogenous
kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons.
Naunyn Schmiedebergs Arch Pharmacol 363: 21–27
Erhardt S, Öberg H, Mathe JM, Engberg G (2001b) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20: 353–
362
Gramsbergen JBP, Hodgkins PS, Rassoulpour A, Turski WA, Guidetti P, Schwarcz R
(1997) Brain-specific modulation of kynurenic acid synthesis in the rat. J Neurochem
69: 290–298
Guidetti P, Okuno E, Schwarcz R (1997) Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res 50: 457–465
Guidetti P, Wu H-Q, Schwarcz R (2000) In situ produced 7-chlorokynurenate provides
protection against quinolinate- and malonate-induced neurotoxicity. Exp Neurol
163: 123–130
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew
BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for
neuronal protection. J Neurochem 78: 842–853
Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K (1998)
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain
kynurenic acid. Br J Pharmacol 124: 391–399
Heyes MP, Brew BJ, Saito K, Quearry BJ, Price RW, Lee K, Bhalla RB, Der M, Markey
SP (1992) Inter-relationships between quinolinic acid, neuroactive kynurenines,
neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1- infected patients. J Neuroimmunol 40: 71–80
Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH (1993) A mechanism
of quinolinic acid formation by brain in inflammatory neurological disease. Brain 116:
1425–1450
Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX
(2001) The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and
increases non-α7 nicotinic receptor expression: physiopathological implications. J
Neurosci 21: 7463–7473
Hodgkins PS, Schwarcz R (1998) Interference with cellular energy metabolism reduces
kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur J
Neurosci 10: 1986–1994
